// App-Quantinova.ai

546 : A phase II prospective trial correlating progression-free survival (PFS) with CYP2D6 activity in patients with metastatic breast cancer treated with tamoxifen: ECOG-ACRIN E3108.

Researchers

Presenter

  • Vered Stearns

Principal Investigators

  • Anne M. O'Neill

  • Bryan P. Schneider

  • David A. Flockhart

  • Todd C. Skaar

  • Minetta C. Liu

  • Caroline A. Lohrisch

  • Matthew P. Goetz

  • Carlos Vallejos Sologuren

  • Joseph A. Sparano

  • Diego Villa

  • Paula Silverman

  • Puneet S. Cheema

  • Dennis Frederic Moore

  • George W. Sledge

Medical Centers

  • School of Medicine and The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD

  • Dana-Farber Cancer Institute, Boston, MA

  • Indiana University School of Medicine, Indianapolis, IN

  • Mayo Clinic, Rochester, MN

  • BC Cancer Agency, Vancouver, BC, Canada

  • Oncosalud - Auna, Lima, Peru

  • Montefiore Medical Center, Bronx, NY

  • British Columbia Cancer Agency, Vancouver, BC, Canada

  • University Hospitals Case Medical Center, Cleveland, OH

  • Healtheast Care, Maplewood, MN

  • Cancer Ctr of Kansas, Wichita, KS

  • Stanford School of Medicine, Stanford, CA

Locations

  • United States

  • Canada

  • Peru

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Cytochrome P450 Family 2 Subfamily D Member 6

Drug/Treatment

  • endoxifen

  • Tamoxifen

Outcome

  • N/A

Study Design

  • Prospective

Phase

  • II

Study Id's

  • NCT01124695CYP2D6

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved